Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial

Thomas C. Krivak, MD, shares the positive results from the RUBY trial of pembrolizumab plus chemotherapy followed by maintenance in patients with dMMR advanced endometrial cancer, supporting its approval and use in this population.

Related Content:

Recent Advances in Treating Endometrial and Cervical CancersGynecologic OncologyOncLive Peer Exchange®

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer

Dr Montero on Potential Advantages With STX-478 in PI3Kα-Mutant Solid Tumors